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Abstract
Background: Huntington’s Disease-like 2 (HDL2) is classified as a neuroacanthocytosis; however, this remains unverified. We aim to determine if acanthocytes
are present in HDL2 and whether acanthocytes can differentiate HDL2 from Huntington’s disease (HD).
Methods: We prospectively compared 13 HD and 12 HDL2 cases against 21 unaffected controls in Johannesburg. Blood smears were prepared using
international standards and reviewed by at least two blinded reviewers. An acanthocytosis rate of greater than 1.2% in the dry smear or greater than 3.7% in the wet
smear was designated a priori as the threshold for clinical significance based on previously established standards. Flow cytometry was performed on all but four of
the cases. Red cell membrane protein analysis was performed on all participants.
Results: There were 12 HDL2, 13 HD, and 21 controls enrolled. None of the HD or HDL2 participants had defined acanthocytosis or other morphological
abnormalities. None of the HD or HDL2 cases had evidence of an abnormal band 3.
Discussion: Acanthocytosis was not identified in either HDL2 or HD in our patient population. Our results, based on the first prospective study of acanthocytes in
HDL2 or HD, suggest that screening for acanthocytes will not help establish the diagnosis of HD or HDL2, nor differentiate between the two disorders and raises
the question if HDL2 should be placed within the neuroacanthocytosis syndromes.
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Introduction
Huntington’s disease-like 2 (HDL2) is an autosomal dominant neuro-
degenerative disorder caused by a CTG/CAG expansion mutation in
exon 2A of junctophilin-3 (JPH3) on chromosome 16q24.3, which occurs
in patients of African ancestry.1 HDL2 is clinically and pathologically
similar to Huntington’s disease (HD), with progressive dementia and
movement abnormalities comprising the predominant clinical phenotype.2
Anecdotal case reports suggested that, compared to HD, eye movement
abnormalities are less common and parkinsonism more common in HDL2.3
Acanthocytes were documented in some of the early reported cases of
HDL2, resulting in diagnostic confusion with chorea–acanthocytosis.4,5
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Acanthocytes are erythrocytes with spiky deformations of their membranes,
and when found in high numbers are associated with many diseases.
The source of acanthocytes in chorea–acanthocytosis, McLeod syndrome,
and pantothenate kinase-associated neurodegeneration (and possibly
also aceruloplasminemia) appears to be complex. Abnormal phos-
phorylation of the proteins connecting the membrane and cytoskeleton
of erythrocytes, erythrocyte metabolism, the involvement of lipids
in underlying signaling pathways, changes in lipid composition, and
signal transduction have all been implicated.6 The relationships of
these potential mechanisms to neurodegeneration are unclear.7
A systematic review of all reported HDL2 patients showed acantho-
cytes were detected in four of 13 cases; however, the hematological
findings in most HDL2 cases are unknown or unreported.3 In three of
these four cases, the affected individuals were members of the same
pedigree, and one individual had a Fragile X mutation (660 triplet
repeats), while the two affected relatives had repeats in the Fragile X
pre-mutation range (57 and 56 repeats). Peripheral smears and electron
microscopy revealed that 30–35% of the red blood cells were acantho-
cytes and red blood cell membrane extract showed an abnormal
breakdown of band 3 proteins.4 The fourth case was from a Mexican
pedigree of likely African descent. Only one of the three family
members with HDL2 had acanthocytes of 35% on peripheral smear,
but cell membrane extracts did not show an abnormal band 3 protein.5
These findings have led to the suggestion that HDL2 be classified
as one the neuroacanthocytosis syndromes, and that the presence of
acanthocytes might provide important insight into HDL2 patho-
genesis, with implications for understanding HD and the neuro-
acanthocytoses. To our knowledge there have been no systematic
efforts to document acanthocytes in HD.
We therefore designed a prospective systematic investigation to study
acanthocytosis in HD and HDL2 patients of the same ethnicity, taking
advantage of our finding that the area around Johannesburg, South Africa,
contains the world’s highest known concentration of HDL2 patients.8
Methods
HD and HDL2 patients with African or mixed ancestry were identi-
fied over 30 months at the Charlotte Maxeke Johannesburg Academic
Hospital Huntington Disease Clinic as part of a larger HDL2 pheno-
type study.3 Ethics clearance was obtained from the Human Research
Ethics Committee of The University of the Witwatersrand (M140872)
and informed consent was obtained from all study participants.
Diagnoses were confirmed by mutation testing for the specific triplet
repeat expansion in the genes causing HD and HDL2 at the Division
of Human Genetics, National Health Laboratory Service. Control
cases, also of African or mixed ancestry, were genetically unrelated
family members or friends of the affected patients.
Blood samples were collected from both the control and either the
HD or the HDL2 subject at the same study visit. Two 5-ml blood samples
were collected, one in Ethylenediaminetetraacetic Acid (EDTA) and the
other in Acid Citrate Dextrose (ACD) (BD Vacutainer Systems, UK).
Each tube was labeled using a non-identifying study number and was
processed within 20 minutes of the venipuncture. The laboratory
was blinded to the diagnosis. Smears were prepared using the same
techniques.
Methods for wet and fixed smears were performed according to
previously established protocols.9 In brief, an aliquot (,5 mL) of whole
blood, collected in EDTA tubes, was used to prepare a fixed smear on
a glass slide and stained using the Rapidiff Stain (Diagnostic Media
Products, South Africa). In parallel, unfixed wet smears were prepared
within an hour of the blood draw. A minimum of 10 fields of each
preparation was examined with a Zeiss Axiostar (Carl Zeiss Jena GmbH,
Germany) microscope under oil immersion at 1,0006 magnification.
Blood was obtained from an unaffected control at the same time and
smears were prepared using the same techniques. An acanthocytosis rate
of greater than 1.2% in the dry smear or greater than 3.7% in the wet
smear was designated a priori as the threshold for clinical significance
based on previously established standards.9
As a third approach to detecting abnormal hematological features
in HDL2, red cell membranes were prepared from blood samples
drawn in ACD tubes as described by Coetzer and Palek.10 The protein
concentration was determined using the Coomassie Plus Protein
Assay Reagent (Pierce Biotechnology Incorporated, USA). Aliquots of
solubilized erythrocyte membrane proteins were prepared by boiling
for one minute in 10 mM Tris-HCl pH 8, 1 mM EDTA, 1% SDS, 5%
sucrose, 2% b-mercaptoethanol, and 20–50 mg of protein was resolved
on a 12% Laemmli SDS-polyacrylamide gel and a 4–17% Fairbanks
gradient gel. Gels were stained with 0.05% Coomassie Blue (BDH
Laboratory Supplies, UK) in 25% isopropanol, 10% acetic acid) and
the amount of band 3 was quantitated using a Hoefer GS300
transmittance/reflectance scanning densitometer and GS365W soft-
ware (Hoefer Scientific Instruments, USA).
The Fisher exact test was used to assess the relationship between
categorized acanthocyte screening test results and groups. Data analysis
was carried out using SAS version 9.4 for Windows. The 5% significance
level was used.
Results
All HDL2 or HD cases enrolled had African or mixed ancestry.
Control cases were genetically unrelated family members or acquain-
tances with African or mixed ancestry of the affected patients. The HD
group included 11 separate pedigrees; two pedigrees each contributed
two individuals to the study. The HDL2 group consisted of 12
unrelated individuals. Two HDL2 patients were also human immuno-
deficiency virus positive and receiving antiretroviral treatment. The
results are presented in Table 1.
The acanthocyte counts remained below the defined normal thre-
sholds in all of the HD, HDL2 and control cases in multiple biological
replicates for both wet and dry smears. There were no other abnormal
erythrocyte features noted on blood smear. The rest of the assessed
flow cytometry for each group can be seen in Table 1 and all were
within normal ranges. The flow cytometry evaluation was not available
in four cases where there was a blood smear available. These were in
three controls and one HD case. The amount of band 3 in the red cell
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Table 1. Comparative Results between HDL2, HD, and Control Groups
HDL2 HD Control
Number of participants 12 13 21
Age (years)
Mean age (SD) 49.2 (¡9.5) 46.8 (¡13.2) 49.5 (¡14.9)
Median age 49 47 52
Range 32–66 32–68 21–79
Disease duration (years)
Mean duration of disease (SD) 5.9 (¡4.3) 8.2 (¡4.7) –
Median duration of disease 6 6
Range 1–18 4–18
Triplet repeat length
Mean abnormal repeat length (SD) 46.3 (¡3.3) 44.3 (¡4.5) –




Wet smear (defined as .3.7% erythrocytes being
acanthocytes)
Positive (number of patients) 0 0 0
Dry smear (defined as .1.2% erythrocytes being
acanthocytes)
Positive (number of patients) 0 0 0
Median % of acanthocytes (IQR) 0.21 (0.06–0.44) 0.06 (0.00–0.11) 0.06 (0.02–0.14)
Erythrocyte analysis (SD)
Hemoglobin (g/dL) 14.62 (¡1.40) 14.28 (¡2.05) 15.56 (¡3.99)
Red cell count (1012/L) 5.01 (¡0.63) 4.91 (¡0.47) 5.08 (¡0.56)
MCV (fL) 88.1 (¡4.2) 87.1 (¡5.6) 87.4 (¡4.9)
MCH (pg) 29.5 (¡2.0) 29.1 (¡2.6) 29.1 (¡2.0)
MCHC (g/dL) 33.3 (¡1.5) 33.3 (¡1.5) 33.3 (¡1.2)
RDW (%) 13.3 (¡0.9) 13.7 (¡1.4) 13.6 (¡0.8)
Abbreviations: IQR, Interquartile Range; MCH, Mean Corpuscular Hemoglobin; MCHC, Mean Corpuscular Hemoglobin Concentrate;
MCV, Mean Corpuscular Volume; RDW, Red cell Distribution Width; SD, Standard Deviation.
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membranes of all the HD, HDL2, and control cases was normal,
which correlates with the normal red cell morphology.
Discussion
There was no evidence of acanthocytosis in any of the HLD2 or HD
patients. Assessments were performed using three different measures,
and compared with a normal control group. We therefore conclude
that acanthocytosis is not a significant component of HDL2 or HD in
our patient population.
The presence of acanthocytosis in four previous cases of HDL2
remains intriguing. In the first three cases the technique for obtaining
the smear described not stressing the erythrocytes with saline or aging
them and that up to 5% acanthocytes/echinocytes was accepted
as being within the normal range.5 Echinocytes are difficult to dif-
ferentiate from acanthocytes on light microscopy and are usually
from smear processing errors whereas acanthocytes are of pathological
relevance. The method we employed for the detection of acanthocytes
by Storch et al.9 was not published until 2005. This method is now
considered to be the gold standard in testing for acanthocytes in
neuroacanthocyte syndromes and reduces echinocytic stress.9 The
method used to detect acanthocytes in the original four cases where
acanthocytes were seen was not described in sufficient detail to
duplicate and therefore the Storch method was used by our group.
Acanthocytes may be an infrequent feature of HDL2, or may only
develop in the presence of other genetic or environmental modifiers.
Three of the four HDL2 cases with acanthocytes were related, and all
carried either the Fragile X mutation or premutation. With hindsight it
may have been useful to have had a Fragile X control group; however,
acanthocytosis has not been reported in either Fragile X or FXTAS
patients. The fourth case did not have abnormal band 3 proteins, and
had HDL2-affected siblings without acanthocytes. All four cases have
subsequently died and are therefore unfortunately not available for
further study.
The pathogenesis of HDL2 appears to be complex, with potential
contributions from a toxic gain-of-function of abnormal JPH3 RNA,11
loss of JPH3 expression,12 and, potentially, expression of an antisense
gene encoding expanded polyglutamine repeats.13 The present study,
although a relatively small sample size, has nearly doubled the number
of HDL2 patients tested for acanthocytes in the literature and for the
first time examined acanthocytes in HD. Our results, based on the first
prospective study of acanthocytes in HDL2 or HD, suggest that
screening for acanthocytes will not help establish the diagnosis of HD
or HDL2, nor differentiate between the two disorders. Further, the
processes underlying acanthocyte formation are unlikely to substan-
tially contribute to the pathogenesis of most cases of HDL2 and HD.
The question is now raised as to whether HDL2 should be grouped
with the neuroacanthocytosis syndromes. Finally, our results continue
to demonstrate the remarkable phenotypic similarities between HD
and HDL2.
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